Previous 10 | Next 10 |
Topline data from an initial six-subject cohort in an open-label, single-arm Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...
ASLAN Pharmaceuticals (NASDAQ: ASLN ) +85% on positive ASLAN004 data. More news on: ASLAN Pharmaceuticals Limited, Akari Therapeutics, Plc, Evofem Biosciences, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 28% premarket on robust volume on the heels of its design of a two-part Phase 3 clinical trial evaluating Coversin (nomacopan) in pediatric patients hematopoietic stem cell transplant-related thrombotic microangiopat...
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration (FD...
Akari Therapeutics (NASDAQ: AKTX ): Q3 GAAP EPS of $0.00. More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
- New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - Clinical progress across our target conditions Phase I...
Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding These new findings suggest that inhibition of both LTB4 and C5 by nomacopan may provide therapeutic effect by reducing bot...
Akari Therapeutics ( AKTX -8.1% ) is down in early trade on the heels of the release of data from an ongoing Phase 2 clinical trial evaluating Coversin (nomacopan) in patients with a rare skin-blistering disorder called bullous pemphigoid (BP). The results are being presented...
PG&E (NYSE: PCG ) -29% on bankruptcy judge decision clearing way for Elliott plan. More news on: PG&E Corporation, Forescout Technologies, Inc., HEXO Corp., Stocks on the move, Read more ...
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients – No reported drug-related serious adverse events – Achieved marked reduction in Bullous Pemphigoid Disease Ar...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...